Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

103. Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial

Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial 28966211 2017 10 02 2017 10 20 0315-162X 2017 10 01 The Journal of rheumatology J. Rheumatol. Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial. jrheum.161407 10.3899/jrheum.161407 To evaluate the initial serological responses to pneumococcal vaccination (...) with the 13-valent protein-conjugated pneumococcal vaccine (PCV13) followed by the 23-valent polysaccharide pneumococcal vaccine (PPV23) among patients with rheumatoid arthritis (RA) treated with biological disease-modifying antirheumatic drugs (bDMARD) according to dosing and intervals between immunizations. Investigator-initiated clinical trial. Patients with RA receiving bDMARD were randomized (1:1:1) to immunization with single dose PCV13 followed by PPV23 after 16 or 24 weeks, or double dose PCV13

EvidenceUpdates2017

104. Case series: Monoarticular rheumatoid arthritis

Case series: Monoarticular rheumatoid arthritis 29308281 2018 11 13 2147-9720 4 4 2017 Dec European journal of rheumatology Eur J Rheumatol Case series: Monoarticular rheumatoid arthritis. 264-267 10.5152/eurjrheum.2017.17011 Monoarticular presentation of rheumatoid arthritis is infrequent and has been previously reported to involve large joints such as the hip and knee joints. Here we report a case series of four patients presenting to the University of Michigan in 2015 with monoarticular (...) rheumatoid arthritis, one with small and three with large joint involvement. In total, four patients with monoarticular rheumatoid arthritis were treated in the Division of Rheumatology, University of Michigan. All the patients were retrospectively reviewed with permission from our Institutional Review Board; informed consent was provided by the patients for enrollment in a clinical trial for patients with rheumatoid arthritis. All the patients were assessed using the 2010 ACR/EULAR classification

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

105. Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis - after DMARD failure

Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis - after DMARD failure Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis - after DMARD failure ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector (...) device] for adult patients with moderate to severe active rheumatoid arthritis - after DMARD failure October 2017 Technology Description: There is currently no cure for rheumatoid arthritis. The most common treatment options are steroids to reduce inflammation, medications to reduce pain and inflammation and medications that slow the progression of joint damage from RA. Tocilizumab is already licensed for the treatment of RA as both intravenous and subcutaneous (pre-filled syringe) formulations

NIHR Innovation Observatory2017

106. Adalimumab impact on fatigue measured by FACIT-F: a study of rheumatoid arthritis patients in Saudi Arabia

Adalimumab impact on fatigue measured by FACIT-F: a study of rheumatoid arthritis patients in Saudi Arabia 29089788 2018 11 13 1179-156X 9 2017 Open access rheumatology : research and reviews Open Access Rheumatol Adalimumab impact on fatigue measured by FACIT-F: a study of rheumatoid arthritis patients in Saudi Arabia. 181-184 10.2147/OARRR.S142411 The objective of the study was to assess the effectiveness of adalimumab as a treatment for fatigue in patients with rheumatoid arthritis (RA (...) . Alzaidi Chair of Research in Rheumatic Diseases, Umm Al-Qura University, Makkah. Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia. eng Journal Article 2017 10 17 New Zealand Open Access Rheumatol 101688698 1179-156X J Clin Oncol. 2003 Jan 15;21(2):366-73 12525531 Ann Oncol. 2009 Jan;20(1):17-25 18678767 J Pain Symptom Manage. 2006 Nov;32(5):420-32 17085268 Arthritis Rheum. 2003 Jan;48(1):35-45 12528101 J Rheumatol. 1996 Aug;23(8):1407-17 8856621 J Rheumatol

Open access rheumatology : research and reviews2017 Full Text: Link to full Text with Trip Pro

107. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial 28939629 2017 09 23 2017 09 23 1468-2060 2017 Sep 22 Annals of the rheumatic diseases Ann. Rheum. Dis. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. annrheumdis-2017-211781 10.1136/annrheumdis (...) -2017-211781 High adalimumab serum concentrations do not result in better response in patients with rheumatoid arthritis (RA), suggesting overexposure. We investigated whether patients with adalimumab concentrations >8 µg/mL can prolong their dosing interval by 50% without a clinically relevant change in disease activity. Consecutive patients with RA, treated with adalimumab 40 mg every other week for at least 28 weeks, were approached for this randomised, open-label, non-inferiority trial. Patients

EvidenceUpdates2017

108. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial 28859326 2017 09 01 2017 09 27 2017 09 27 1462-0332 56 9 2017 Sep 01 Rheumatology (Oxford, England) Rheumatology (Oxford) Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. 1586-1596 10.1093/rheumatology/kex223 To assess the efficacy and safety of initial COBRA-light vs COBRA (...) 9PHQ9Y1OLM Prednisolone YL5FZ2Y5U1 Methotrexate AIM IM Adult Aged Antirheumatic Agents administration & dosage adverse effects therapeutic use Arthritis, Rheumatoid diagnostic imaging drug therapy Comorbidity Disease Progression Drug Administration Schedule Drug Therapy, Combination Female Follow-Up Studies Humans Male Methotrexate administration & dosage adverse effects therapeutic use Middle Aged Prednisolone administration & dosage adverse effects therapeutic use Radiography Severity of Illness Index

EvidenceUpdates2017

110. [Tofacitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V]

[Tofacitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V] Tofacitinib (Rheumatoide Arthritis): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-18 [Tofacitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V] Tofacitinib (Rheumatoide Arthritis): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-18 [Tofacitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V (...) ] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tofacitinib (Rheumatoide Arthritis): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-18. [Tofacitinib (rheumatoid arthritis) - benefit assessment

Health Technology Assessment (HTA) Database.2017

111. Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis

Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis 28936808 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis. 405-417 10.1007/s40744-017-0081-3 Tocilizumab (TCZ) monotherapy has been proven as an effective treatment for rheumatoid arthritis (RA) in clinical trials (...) ):1797-808 10513792 Ann Rheum Dis. 2007 Nov;66(11):1473-8 17426065 J Rheumatol. 2009 Nov;36(11):2435-42 19833759 J Rheumatol. 2007 Feb;34(2):280-9 17304654 Perspect Clin Res. 2011 Oct;2(4):137-44 22145124 Biological therapy Monotherapy Patient-reported outcome measures Rheumatoid arthritis Tocilizumab 2017 05 02 2017 9 25 6 0 2017 9 25 6 1 2017 9 23 6 0 ppublish 28936808 10.1007/s40744-017-0081-3 10.1007/s40744-017-0081-3 PMC5696293

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

112. Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis

Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis 28823986 2017 08 21 2017 08 21 1468-2060 2017 Aug 20 Annals of the rheumatic diseases Ann. Rheum. Dis. Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis. annrheumdis-2017-211608 10.1136/annrheumdis-2017-211608 Patients with rheumatoid arthritis (RA) are at increased risk of acute coronary syndrome (ACS) and suffer from poorer (...) syndrome epidemiology outcome rheumatoid arthritis secondary prevention Competing interests: AM and MH have nothing to declare. TJ reports personal fees from Astra Zeneca, personal fees from MSD, personal fees from Aspen, outside the submitted work. SWJ reports a fee for short talk at conference for Swedish cardiologists and general practitioners January 2016, arranged by Merck, Sharp & Dome. JA and Karolinska Institutet had research agreements with Abbvie, BMS, MSD, Pfizer, Roche, Astra-Zeneca, Lilly

EvidenceUpdates2017

113. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study 28855173 2017 08 31 2017 08 31 1468-2060 2017 Aug 30 Annals of the rheumatic diseases Ann. Rheum. Dis. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. annrheumdis-2017-211328 10.1136/annrheumdis-2017-211328 Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine (...) GlaxoSmithKline Research and Development, Stevenage, Hertfordshire, UK. eng Journal Article 2017 08 30 England Ann Rheum Dis 0372355 0003-4967 DMARDs (biologic) DMARDs (synthetic) cytokines rheumatoid arthritis treatment Competing interests: TT: grant/research support from Astellas Pharma, Bristol-Myers K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin

EvidenceUpdates2017

114. Risk of Obstructive Sleep Apnea and Its Association with Cardiovascular and Noncardiac Vascular Risk in Patients with Rheumatoid Arthritis: A Population-based Study

Risk of Obstructive Sleep Apnea and Its Association with Cardiovascular and Noncardiac Vascular Risk in Patients with Rheumatoid Arthritis: A Population-based Study 28765254 2017 08 02 2017 09 14 0315-162X 2017 Aug 01 The Journal of rheumatology J. Rheumatol. Risk of Obstructive Sleep Apnea and Its Association with Cardiovascular and Noncardiac Vascular Risk in Patients with Rheumatoid Arthritis: A Population-based Study. jrheum.170460 10.3899/jrheum.170460 To define the incidence (...) of obstructive sleep apnea (OSA) in patients with rheumatoid arthritis (RA) and determine whether OSA diagnosis predicts future cardiovascular disease (CVD) and noncardiac vascular events. Medical information pertaining to RA, OSA, CVD, and vascular diagnoses was extracted from a comprehensive medical record system for a geographically defined population of 813 patients previously diagnosed with RA and 813 age- and sex-matched comparator subjects. The risk for OSA in persons with RA versus comparators

EvidenceUpdates2017

115. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial

Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial 28724365 2017 07 20 2017 08 17 1471-2474 18 1 2017 Jul 19 BMC musculoskeletal disorders BMC Musculoskelet Disord Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from (...) a randomized double blind controlled clinical trial. 310 10.1186/s12891-017-1673-3 The standard dose of rituximab used in rheumatoid arthritis (RA) is 1000 mg but recent studies have shown that low dose (500 mg) is also effective. Efficacy of low dose rituximab in rheumatoid arthritis (RA) refractory to first-line non-biologic Disease Modifying Anti Rheumatic Drugs (DMARDs), compared to leflunomide is unknown. In a tertiary care referral setting, we conducted a randomized, double blind controlled clinical

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

116. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study 28798049 2017 08 11 2017 09 06 1468-2060 2017 Aug 10 Annals of the rheumatic diseases Ann. Rheum. Dis. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. annrheumdis-2017-211259 10.1136/annrheumdis-2017-211259 To assess the effect (...) of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once daily (n=487), or adalimumab 40 mg biweekly (n=330) with background MTX. PROs included the SF-36, EuroQol 5-D (EQ-5D) index scores and visual analogue scale, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire

EvidenceUpdates2017

117. [Baricitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V]

[Baricitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V] Baricitinib (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14 [Baricitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V] Baricitinib (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14 [Baricitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V (...) ] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Baricitinib (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14. [Baricitinib (rheumatoid arthritis) - benefit assessment

Health Technology Assessment (HTA) Database.2017

118. Clinically stable rheumatoid arthritis - musculoskeletal ultrasound

Clinically stable rheumatoid arthritis - musculoskeletal ultrasound Clinically stable rheumatoid arthritis - musculoskeletal ultrasound: evidence note 70 Search the full site Search keywords Our on-going projects: Evidence note 70 Evidence note 70 Contact the SHTG team Contact Healthcare Improvement Scotland with any SHTG questions: Email: Lead Health Services Researcher Lead for SHTG SHTG Project Officer Evidence note 70 What is the clinical effectiveness, cost effectiveness and safety of home (...) and mobile health monitoring in addition to usual care compared with usual care for adults with diabetes (Type 1 and Type 2)? Downloads Key points Musculoskeletal ultrasound is an imaging technique that has potential to inform decisions on tapering or discontinuation of therapy in rheumatoid arthritis patients who are in clinical remission. Two systematic reviews of observational studies, with overlapping included studies, found that synovitis detected by musculoskeletal ultrasound predicted risk

Evidence Notes from Healthcare Improvement Scotland2017

119. Rheumatoid arthritis - musculoskeletal ultrasound

Rheumatoid arthritis - musculoskeletal ultrasound Rheumatoid arthritis - musculoskeletal ultrasound: Advice Statement 006-17 Search the full site Search keywords Our on-going projects: Advice Statement 006-17 Advice Statement 006-17 Contact the SHTG team Contact Healthcare Improvement Scotland with any SHTG questions: Email: Lead Health Services Researcher Lead for SHTG SHTG Project Officer Advice Statement 006/17 In patients with suspected rheumatoid arthritis, does the addition (...) of musculoskeletal ultrasound increase the ability of rheumatologists to confirm or rule out a diagnosis of rheumatoid arthritis at an earlier stage compared to conventional diagnostic assessment alone? Downloads Review This Advice Statement represents the view of the SHTG at the date of first publication. This Advice Statement will be considered for review 2 years post-publication, and at 2-yearly intervals thereafter. Published Date: 22 September 2017 Related pages NHS Scotland

SHTG Advice Statements2017

120. Clinically stable rheumatoid arthritis - musculoskeletal ultrasound

Clinically stable rheumatoid arthritis - musculoskeletal ultrasound Clinically stable rheumatoid arthritis - musculoskeletal ultrasound: Advice Statement 007-17 Search the full site Search keywords Our on-going projects: Advice Statement 007-17 Advice Statement 007-17 Contact the SHTG team Contact Healthcare Improvement Scotland with any SHTG questions: Email: Lead Health Services Researcher Lead for SHTG SHTG Project Officer Advice Statement 007/17 In patients with clinically stable rheumatoid (...) arthritis (clinical remission), can musculoskeletal ultrasound in addition to clinical examination detect or rule out inflammation that predicts subsequent joint damage to inform tapering and stopping treatment? Downloads Review This Advice Statement represents the view of the SHTG at the date of first publication. This Advice Statement will be considered for review 2 years post-publication, and at 2-yearly intervals thereafter. Published Date: 21 September 2017 Related pages NHS Scotland

SHTG Advice Statements2017